Investigational drug · Phase 3
Netakimab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Plaque Psoriasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "Netakimab"
First trial start
2024
Jul 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Netakimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "Netakimab" as an intervention, largest first.
- International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing SpondylitisPivotal-lookingCompleted
BiocadIndustry
NCT03447704 · 228 participants · Start Feb 9, 2018 · Primary completion Dec 24, 2018
Drug: BCD-085 · For: Ankylosing Spondylitis
Sites: Chelyabinsk, Russia; Kazan', Russia; Moscow, Russia · 7 sites in all
- To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
SPH-BIOCAD (HK) LimitedIndustry
NCT07008547 · 202 participants · Start Jul 30, 2024 · Primary completion Mar 28, 2025
Drug: Netakimab; Placebo · For: Plaque Psoriasis
Sites: Beijing, China
- COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMUCompleted
Pirogov Russian National Research Medical UniversityAcademic, hospital or other
NCT05302947 · 154 participants · Start Feb 1, 2020 · Primary completion Aug 31, 2020
Drug: Baricitinib Oral Tablet; Tocilizumab Injection and 1 more · For: COVID-19; Mild to Moderate
Sites: Moscow, Russia · 2 sites in all
- Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque PsoriasisPivotal-lookingActive, not recruiting
BiocadIndustry
NCT06640517 · 140 participants (planned) · Start Aug 8, 2024 · Primary completion Jun 2026
Drug: Netakimab; Placebo and 1 more · For: Plaque Psoriasis
Sites: Barnaul, Russia; Chelyabinsk, Russia; Kazan', Russia · 14 sites in all
- Evaluate the Efficacy, Safety, and Pharmacokinetic Profile and Immunogenicity of Subcutaneous Netakimab in Chinese Adult Patients With Active Ankylosing SpondylitisPivotal-lookingCompleted
SPH-BIOCAD (HK) LimitedIndustry
NCT07277179 · 113 participants · Start Mar 20, 2023 · Primary completion Jul 5, 2024
Drug: Netakimab; Placebo · For: Ankylosing Spondylitis
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review.
Ameer OZ, Temsah R, Alsouss YO, et al. · Front Pharmacol 2026
- Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: Two-Year Results of the Real Word Evidence LIBRA Study.
Erdes SF, Mazurov VI, Gaidukova IZ, et al. · Dokl Biochem Biophys 2026
- Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders.
Saran A, Nishizaki D, Lippman SM, et al. · Cytokine Growth Factor Rev 2025
- Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review.
Kim D, Yang S, Gill M, et al. · Am J Clin Dermatol 2025
- Comprehensive Insights into Psoriasis: Pathophysiology, An Advanced Exploration of Current Landscape and Future Prospects in "Therapeutic Strategies".
Monis M, Mathur P, Ritu, et al. · Recent Adv Inflamm Allergy Drug Discov 2025
- Efficacy and Safety of Interleukin-17 and Janus Kinase Inhibitors in Ankylosing Spondylitis: A Systematic Review and Network Meta-Analysis.
Liu X, Zhao X, Li M, et al. · Int Arch Allergy Immunol 2025
Also in development for Plaque Psoriasis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- EnvudeucitinibPhase 34 trials
Alumis Inc · Plaque Psoriasis, SLE
- ICP-332Phase 34 trials
Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- piclidenosonPhase 32 trials
Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.